Dyskinesias: all 272 studies
Page 3 of 3. Open to participants first (42), then studies with results posted, then the rest; newest registration first within each.
- A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive DyskinesiaWithdrawnNCT02064010Phase 2
- Evaluation of the Safety of the Medical Device Simeox®TerminatedNCT02061852Not applicable
- A Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound for Unilateral Pallidotomy in the Treatment of Dyskinesia of Parkinson's DiseaseCompletedNCT02003248Phase 1
- Scapular Dyskinesis: a Reliability and Validity Study of Comprehensive Classification TestCompletedNCT01962727
- Famotidine for Levodopa-induced Dyskinesia in PDCompletedNCT01937078Phase 2
- Pyridoxal Kinase Activity in Tardive DyskinesiaWithdrawnNCT01908452Phase 3
- D-Serine Treatment For Tardive DyskinesiaStatus unknownNCT01804920Not applicable
- Wearable Movement Sensors for Assessing Motor Impairments and Dyskinesias in Parkinson DiseaseCompletedNCT01648803
- Global Postural Reeducation and Segmental Exercises in Patients With Scapular Dyskinesis and CervicalgiaCompletedNCT01568840Phase 1
- Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's DiseaseCompletedNCT01538329Phase 2
- Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced DyskinesiasCompletedNCT01491932Phase 2
- Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced DyskinesiasCompletedNCT01491529Phase 2
- Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's DiseaseCompletedNCT01474421Phase 2
- The Assessment of Movement Disorders Utilizing Live Two-Way VideoCompletedNCT01467089
- Capturing Parkinson's Disease Medication Side Effects During Daily ActivitiesCompletedNCT01429207
- Melatonin Treatment for Tardive Dyskinesia in SchizophreniaCompletedNCT01391390Not applicable
- Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced DyskinesiasCompletedNCT01385592Phase 2
- Comparison of the Incidence of Dyskinesia in Parkinson's Disease Who Were Treated With Amantadine or Dopamine AgonistStatus unknownNCT01338662
- ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's DiseaseCompletedNCT01336088Phase 2
- Efficacy and Safety of NBI-98854 in Subjects With Tardive DyskinesiaCompletedNCT01267188Phase 2
- Single-Incision Laparoscopic Cholecystectomy Versus Traditional Laparoscopic CholecystectomyTerminatedNCT01195285Not applicable
- Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced DyskinesiasCompletedNCT01173731Phase 2
- A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With "Wearing Off" Motor Fluctuations and "On" Period DyskinesiasCompletedNCT01172379Phase 2
- Inflammatory and Microbiologic Markers in Sputum: Comparing Cystic Fibrosis With Primary Ciliary DyskinesiaCompletedNCT01155115Not applicable
- Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease SubjectsCompletedNCT01113320Phase 2
- Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced DyskinesiaCompletedNCT01092065Phase 2
- Early Detection and Characterization of Primary Ciliary DyskinesiaStatus unknownNCT01070914
- Natural History of Levodopa-Induced Dyskinesia (LID)WithdrawnNCT01003002
- Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's DiseaseCompletedNCT00986414Phase 2
- Natural Orifice Translumenal Endoscopic Surgery (NOTES) Transvaginal CholecystectomyCompletedNCT00984100Not applicable
- Single Incision Laparoscopic Surgery (SILS) Versus Laparoscopic CholecystectomyCompletedNCT00981604Not applicable
- Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa TherapyCompletedNCT00957918Phase 1/2
- Tardive Dyskinesia and Cognitive FunctionCompletedNCT00926965Phase 4
- Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive DyskinesiaTerminatedNCT00917293Phase 2
- Prospective Evaluation of Forceplate Measured Levodopa-Induced DyskinesiaCompletedNCT00912977
- A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.TerminatedNCT00903838Phase 2
- Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa PharmacokineticsCompletedNCT00888186Phase 4
- Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease PatientsCompletedNCT00888004Phase 2
- Aripiprazole for Neuroleptic-Induced Tardive DyskinesiaStatus unknownNCT00837707Phase 4
- Transvaginal Cholecystectomy Using Endoscopic AssistanceWithdrawnNCT00815438Phase 1
- Diagnosis of Primary Ciliary DyskinesiaCompletedNCT00783887
- Screening for Primary Ciliary Dyskinesia Using Nasal Nitric OxideStatus unknownNCT00739817
- Ultrasound for Diagnosis of Biliary DyskinesiaTerminatedNCT00737295Not applicable
- Long-term Lung Function and Disease Progression in Children With Early Onset Primary Ciliary Dyskinesia Lung DiseaseCompletedNCT00722878
- Extract of Ginkgo Biloba and Tardive DyskinesiaCompletedNCT00672373Phase 3
- Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive DyskinesiaCompletedNCT00621998Phase 4
- Dyskinesia, Heterotaxy and Congenital Heart DiseaseCompletedNCT00608556
- Safety, Tolerability, PK and PD Study of Neu-120 in the Treatment of Levodopa-induced DyskinesiaTerminatedNCT00607451Phase 1/2
- Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients, and Safety in Combination With L-dopaCompletedNCT00582673Phase 2
- Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's DiseaseTerminatedNCT00477802Phase 4
- The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole TrialStatus unknownNCT00468533Phase 4
- Evaluating Progression of and Diagnostic Tools for Primary Ciliary Dyskinesia in Children and AdolescentsCompletedNCT00450918
- Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in SchizophreniaCompletedNCT00401089Phase 1/2
- Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson'sCompletedNCT00363727Phase 3
- Rare Genetic Disorders of the Breathing AirwaysCompletedNCT00323167
- Sarizotan in Parkinson Patients With L-dopa-induced DyskinesiaCompletedNCT00314288Phase 2
- Sarizotan in the Treatment of Neuroleptic-induced Tardive DyskinesiaTerminatedNCT00310661Not applicable
- Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's DiseaseCompletedNCT00307450Phase 4
- Topiramate as a Treatment for Levodopa-Induced Dyskinesia in Parkinson's DiseaseTerminatedNCT00296959Phase 2
- Levetiracetam Administration for the Management of Levodopa-Induced Dyskinesias in Parkinson's DiseaseStatus unknownNCT00291733Phase 2
- Levetiracetam Treatment of Tardive DyskinesiaCompletedNCT00291213Phase 3
- Movement Disorders Caused by Antipsychotic Drugs in Older PatientsCompletedNCT00255879Phase 1
- Piracetam for Treatment Tardive DyskinesiaCompletedNCT00190008Phase 3
- Levetiracetam in the Treatment of Neuroleptic-induced Tardive DyskinesiaCompletedNCT00175955Phase 2
- Treatment of Tardive Dyskinesia With GalantamineCompletedNCT00164242Phase 4
- Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome DyskinesiasCompletedNCT00160576Phase 2
- Ethyl-Eicosapentaenoic Acid and Tardive DyskinesiaCompletedNCT00114595Phase 4
- ACP-103 to Treat Parkinson's DiseaseCompletedNCT00086294Phase 2
- Levetiracetam Treatment of L-dopa Induced DyskinesiasCompletedNCT00076674Phase 2
- Effects of Talampanel on Patients With Advanced Parkinson's DiseaseCompletedNCT00036296Phase 1/2
- Genetic Study of Patients With Primary Ciliary DyskinesiaCompletedNCT00005650
- Study of LY300164 for the Treatment of Parkinson's DiseaseCompletedNCT00004576Phase 2